Obamacare enrollments in health insurance exchanges for the 2025 enrollment period have reached 24.2M, an all-time high. Read ...

The Centers for Medicare and Medicaid Services (CMS) has selected 15 more drugs for Medicare price negotiation, announcing ...

The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...

BECERRA’S FINAL ACT — During the unveiling of his official portrait on Tuesday, HHS Secretary Xavier Becerra ... is returning as CMS chief operating officer. — Drew Snyder is expected ...

The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration.

CMS has named 15 additional prescription drugs, including diabetes medication Ozempic, for price negotiations under the Inflation Reduction Act. This marks the second round of negotiations aimed at ...

The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, ...

The Centers for Medicare and Medicaid Services (CMS) on Friday announced 15 additional Medicare Part D drugs selected for the ...

The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs, for the second annual round of drug price ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Associations and providers representing home care and hospice in Texas, Indiana, North Carolina and South Carolina sued HHS.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.